On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

As has been the trend in 2020, Taysha Gene Ther­a­pies has be­come the lat­est biotech to make a quick as­cent from a small, pri­vate­ly-fund­ed com­pa­ny to en­joy­ing its very own Nas­daq tick­er.

The Dal­las-based biotech raised $157 mil­lion for its IPO af­ter pric­ing shares at $20 apiece Thurs­day, the high-point of its ex­pect­ed range. Ini­tial­ly peg­ging $100 mil­lion in fi­nanc­ing, Taysha of­fered a lit­tle less than 8 mil­lion shares and will trade un­der the $TSHA sym­bol.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA